 San Diego, Calif., Feb. 03, 2021 GLOBE NEWSWIRE -- Skye Bioscience, Inc. OTCQB: SKYE SKYE or the Company, a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced that members of its leadership team will present at several upcoming investment events in February, including the Small-Cap Growth Investor Conference, the Money Show February Virtual Expo, and the Benzinga Cannabis Capital Conference taking place virtually. 